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Objective. We evaluated the prognostic role of circulat-
ing cardiovascular biomarkers in patients with a his-
toryof recentatrialfibrillation (AF).
Background. Predicting long-termmaintenance of sinus
rhythminpatientswithAF isdifficult.
Methods. Plasma concentrations of three specific car-
diac markers [high-sensitivity troponin T (hsTnT),
N-terminal probrain natriuretic peptide (NT-proBNP)
and mid-regional proatrial natriuretic peptide (MR-
proANP)] and three stable fragments of vasoactive
peptides [mid-regional proadrenomedullin (MR-
proADM), copeptin (CT-proAVP) and CT-proendoth-
elin-1 (CT-proET-1)] were measured at baseline and
after 6 and12 months in 382 patients enrolled in the
GISSI-AF study, a prospective randomized trial to
determine the effect of valsartan to reduce the recur-
rence of AF. The association between these markers,
clinical characteristics and recurrence of AF was
testedbyunivariateandmultivariateCoxmodels.
Results. Mean patient age was 68 ± 9 years (37.2%
females). A total of 84.8% of patients had a history of
hypertension. In total, 59.7% qualified for history of
AF because of successful cardioversion, 11.8% be-
cause of two or more episodes of AF in the 6 months
preceding randomizationand28.5%becauseofboth.
Patients in AF at 6 or 12 months (203 (53.1%) with
first recurrence) had significantly higher concentra-
tionsofmostbiomarkers.Despite lowbaseline levels,
higher concentrations of hsTnT {adjusted hazard ra-
tio (HR) [95%confidence intervals (CIs) for1 SDincre-
ment] (1.15 [1.04–1.28], P = 0.007), MR-proANP
(1.15 [1.01–1.30], P = 0.04), NT-proBNP (1.24 [1.11–
1.39],P = 0.0001)andCT-proET-1 (1.16 [1.01–1.33],
P=0.03) independentlypredictedhigher risk of afirst
recurrence of AF. Changes over time of MR-proANP
tended to predict subsequent recurrence (adjusted
HR[95%CI]) (1.53[0.98–2.37],P = 0.06).
Conclusion. Circulating markers of cardiomyocyte in-
jury ⁄strain and endothelin are related to recurrence
of AF in patients in sinus rhythmwith a history of re-
centAF.
Keywords: atrial fibrillation, natriureticpeptides, prog-
nosis, troponinT.
Abbreviations: AF, atrial fibrillation; ARB, angiotensin
receptor blocker; CT-proAVP, copeptin or C-terminal
provasopressin; CT-proET-1, C-terminal proendoth-
elin-1; hsTnT, high-sensitivity cardiac troponin T;
MR-proADM, mid-regional proadrenomedullin; MR-
proANP, mid-regional proatrial natriuretic peptide;
NT-proBNP,N-terminalprobrainnatriureticpeptide.
*Acomplete listof thestudyinvestigators ispresented
intheAppendix.
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Introduction
Atrial fibrillation (AF) recurswithin thefirst year after
successful cardioversion inabout50%ofpatients [1].
Predictors of recurrencemayhelp inplanning the fre-
quency of planned clinical visits, inmodulating ther-
apyand inbetterunderstanding thepathophysiology
of the disease. Whilst several studies have reported
increased concentrations of cardiovascular markers
in patients with AF [2–7], few studies have assessed
the predictive roles of thesemarkers in patients in si-
nus rhythm at high risk of AF [8, 9]. Given the com-
plexity of studies in thisfieldbecause of theheteroge-
neity of populations and the limitations in terms of
sample size, it canbe concluded that in general natri-
uretic peptides are elevatedduringAF andpredict AF
recurrence or first occurrence in patients with vari-
ous comorbidities [3], hypertension [10] and heart
failure [11], or those who have undergone cardiac
surgery [12]. Major limitations of these studies in-
clude small sample size (<100 patients) and ⁄or retro-
spectivedesign.
GISSI-AF, a trial to determine the effect of valsartan
in preventing recurrence of AF in patients in sinus
rhythm [13], appeared to be a suitable setting to
investigate how different biomarkers would predict
recurrenceofAF.Accordingly, sixdifferentcardiovas-
cular markers were assayed in 382 patients enrolled
in the GISSI-AF trial. High-sensitivity cardiac tropo-
nin T (hsTnT) and N-terminal probrain natriuretic
peptide (NT-proBNP)weremeasuredas sensitive and
specificmarkers of cardiac injury ⁄strain ⁄filling pres-
sures. Mid-regional proatrial natriuretic peptide
(MR-proANP) was assayed as it is considered to best
reflect atrial strain, a determinant of AF.Amongst the
three vasoactive peptides, C-terminal proendothelin-
1 (CT-proET-1)wasmeasuredbecause of the relation
betweenendothelinandnew-onsetAF inheart failure
[12] andbecause of its possible role in thepathogene-
sis of AF [14, 15]. Mid-regional proadrenomedul-
lin (MR-proADM) and C-terminal provasopressin
(copeptin) have been found to be related to the
altered haemodynamics and volume load in heart
failure [16,17].
Patients andmethods
The GISSI-AF trial was a randomized, double-blind,
placebo-controlled, multicentre study that enrolled
1442patientswhowere in sinus rhythmbut hadhad
either two or more documented episodes of AF in the
previous6 monthsorsuccessful cardioversion forAF
in the previous 2 weeks (qualifying history of AF). To
be eligible for the study, patients also had to have
underlyingcardiovasculardisease,diabetesor leftat-
rial enlargement.Theaimof the trialwastodetermine
whether valsartan could reduce the recurrence of AF
[13, 18]. In a subset of 382 patients recruited in 36
clinical centres (see Appendix), blood samples were
drawn at randomization and after 6 and 12 months
of follow-up. Patients remained supine for at least
15 min before blood was collected using an indwell-
ing venous cannula. Blood was centrifuged at 4 C
within10 min, andplasmaaliquotswere sent, ondry
ice, to a central laboratory. Samples were stored for
up to2 yearsat)70 Cuntil required forassay.
Study visits were scheduled at weeks 2, 4, 8, 24 and
52. A routine clinical examination, including electro-
cardiography (ECG) and laboratory testing, was per-
formed at each study visit. To increase the likelihood
of AF detection, all patients were provided with a
transtelephonic monitoring device (Cardiobios 1;
Telbios, Milan, Italy). Patients were asked to activate
the device, which would transmit a 30-s electrocar-
diogram to both the coordinating centre and the
responsible physician, if symptoms occurred and at
leastonceaweekwhetherornot symptomsoccurred.
If a recurrence of AF was detected, patients were
asked to come in for an office visit to confirm thefind-
ings. Each AF episode during the trial was adjudi-
cated blindly bya central reader and verifiedbyanad
hocvalidationcommittee.
Determination of biomarker concentrations
The six biomarkers were assayed in a central labora-
tory in a blinded fashion in EDTA-anticoagulated
plasma. Measurements of B-type natriuretic peptide
and endothelin-1 were prespecified in the protocol
[18]. Plasma concentrations of MR-proANP, MR-
proADM, CT-proET-1 and copeptin were measured
with chemiluminescence immunoassays (BRAHMS
AG, Henningsdorf, Germany). The limits of detection
of these assays were 6 pmol L)1 for MR-proANP,
0.08 nmol L)1 for MR-proADM, 0.4 pmol L)1 for CT-
proET-1 and 1.7 pmol L)1 for copeptin. The sensitiv-
ity of the functional assay, defined as the concentra-
tion at which the interassay coefficient of variation
(CV) was 10%, was 65 pmol L)1 for MR-proANP,
0.4 nmol L)1 for MR-proADM, 10 pmol L)1 for CT-
proET-1 and 9 pmol L)1 for copeptin. The normal
reference ranges for the four biomarkers have been
published previously and are expressed as median
[2.5th–97.5thpercentiles] as follows:MR-proANP,45
[18.4–163.9] pmol L)1; MR-proADM, 0.33 [0.17–
0.49] nmol L)1; CT-proET-1, 44.3 [24.8–66.6]
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pmol L)1; copeptin, 4.2 [1.7–11.25] pmol L)1.
NT-proBNP and hsTnT were measured using an
electrochemiluminescence immunoassay method
(Elecsys 2010 analyzer; Roche Diagnostics, Rotk-
reuz, Switzerland), as previously described [19, 20].
The 99th percentile cut-off for hsTnT from 616
healthy reference subjects was 13.5 pg mL)1, and
theCVwas9%[21].
Statistical methods
Baseline characteristics of study patients by first AF
recurrence were compared by chi-square test or by t-
test. Concentrations of the biomarkers were ex-
pressed as median [quartile 1–quartile 3]. Median
concentrations of the biomarkers were compared by
nonparametric Wilcoxon rank-sum test or Kruskal–
Wallis testwhenappropriate.
The association between biomarker concentrations
andfirst recurrenceofAFwasevaluatedovera follow-
upperiodof1 year. Theassociationbetweenbaseline
concentration of each biomarker andfirst recurrence
of AF was assessed by univariate Cox proportional
hazards models. Biomarkers were modelled as con-
tinuous variables (expressed as 1 SD increment) as
linearity of the hazard was tested by appropriate
transformation using restricted cubic splines to
account for possible nonlinear relationships. Cox
multivariate models were performed to evaluate the
independent prognostic value of eachbiomarker sep-
arately; adjusting for baseline covariates emerged as
statistically significant from the stepwise selection
procedure (P < 0.05), i.e. qualifying history of AF,
smoking, documented coronary artery disease and
history of lone AF with atrial dilatation. The prognos-
tic discrimination of each biomarker for first AF
recurrencewasevaluatedby theareaunder the recei-
ver operating characteristic curve (AUROC). We also
investigated whether the addition of different combi-
nations of the biomarkers improved the discrimina-
tion of the model. Estimates of the C-statistic for the
Cox regression models were calculated according to
the method of Pencina et al. [22]. Kaplan–Meier
curves for the probability of first recurrence of AF
wereplotted forbaselineconcentrationsof thesixbio-
markers according to their median cut-off value and
compared by the log-rank test. Similarly, the inde-
pendent prognostic value of each biomarker on all-
cause and cardiovascular hospitalizations was as-
sessedbyunivariateandmultivariateCoxmodels.
Concentrations of all biomarkers in patients who
were in sinus rhythm compared with those in AF at
the 6-month and 12-month scheduled ECG record-
ingswerecomparedbyWilcoxonrank-sumtest.
Each biomarker measured at baseline, 6 and 12
months was analysed in terms of within-patient
changes over time for first AF recurrence. A repeated-
measuresanalysis of variance (anova)wasperformed
on the biomarker concentrations transformed on a
logarithmicscale.
To evaluate the prognostic value of changes in bio-
marker concentrations over 6 months on the risk of
AF recurrence, relative changes of each marker
[(6 months–baseline) ⁄baseline] were calculated. For
those patients in sinus rhythm at 6 months’ follow-
up, univariate and multivariate Cox models were
used to assess the association between changes
(median value cut-off) in the biomarkers and the first
occurrence of AF within the next 6 months (6–
12 months).
All probability values are two-tailed, and 95% confi-
dence intervals (CIs) were calculated. Because of the
exploratory nature of this study, adjustments for the
multiplicity of statistical analyses have not been
made. Statistical analyses were performed with sas
software, version 9.1 (SAS Institute, Cary, NC, USA)
andwith theprogramRand thepackage rms (http://
CRAN.R-project.org/package=rms).
Results
Baseline characteristics
Baseline characteristics of the study patients overall
and by first recurrence of AF are shown in Table 1.
The only statistically significant differences between
patients who did and did not have a recurrence of AF
were sex and qualifying history of AF: males and pa-
tientswith two ormore episodes of AF in the previous
6 months were more likely to have a recurrence of
AF.
The characteristics of the 382patients in the biomar-
ker substudy were almost identical to those of the
main GISSI-AF trial (data not shown, [13]). Accord-
ingly, 53.1% (203 ⁄382) of patients had a first recur-
rence of AF over 1 year of follow-up in the substudy,
compared to 51.7% (746 ⁄1442) in the main study.
Similar consistency of outcomes was also found for
the coprimary end-point, more than one recurrence
of AF, and for the secondary end-points of GISSI-AF.
The rate of all-cause deathswas 0.26% (1 ⁄382) in the
substudyand1.0% (15 ⁄1442) in themain study, and
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Table 1 Baselinepatientcharacteristicsaccording tofirst recurrenceofAF
Characteristics
Allpatients
(n = 382)
Patientswith‡1
recurrenceofAF
(n = 203)
Patientswithout
recurrenceofAF
(n = 179) Pvalue
Females,n (%) 142 (37.2) 65 (32.0) 77(43.0) 0.03
Age,mean ± SD(years) 68.1 ± 9.1 67.8 ± 9.2 68.4 ± 9.0 0.54
BMI,mean ± SD(kg m)2) 27.9 ± 4.3 27.9 ± 3.9 27.8 ± 4.7 0.84
Systolicbloodpressure,mean ± SD(mmHg) 138.3 ± 16.5 137.4 ± 16.2 139.2 ± 16.8 0.29
Diastolicbloodpressure,mean ± SD(mmHg) 81.2 ± 8.4 80.6 ± 8.7 81.8 ± 8.1 0.15
EstimatedGFR,mean ± SD(ml min)1 1.73 m)2) 72 ± 18 73 ± 17 71 ± 18 0.39
Inclusioncriteria
‡2episodesofAF inprevious6 months,n (%)a 154 (40.9) 93 (46.3) 61(34.7) 0.02
Cardioversion inprevious2 weeks,n (%)a 336 (88.0) 174 (85.7) 162 (90.5) 0.15
Heart failure,LVEF<40%,orboth,n (%) 42(11.0) 25 (12.3) 17(9.5) 0.38
Historyofhypertension,n (%) 324 (84.8) 167 (82.3) 157 (87.7) 0.14
Diabetesmellitus,n (%) 50(13.1) 28 (13.8) 22(12.3) 0.66
Historyof stroke,n (%) 15(3.9) 7 (3.5) 8 (4.5) 0.61
Peripheralarterydisease,n (%) 22(5.8) 15 (7.4) 7 (3.9) 0.15
DocumentedCAD,n (%) 41(10.7) 25 (12.3) 16(8.9) 0.29
SingleAFepisodewithLAdilatation,n (%) 52(13.6) 33 (16.3) 19(10.6) 0.11
Durationof lastqualifyingepisodeofAF>7 days,n (%) 151 (39.5) 80 (39.4) 71(39.7) 0.94
Comorbidities
Peripheral embolism,n (%) 4 (1.1) 3 (1.5) 1 (0.5) 0.38
Renaldysfunction,n (%) 10(2.6) 5 (2.5) 5 (2.8) 0.84
COPD,n (%) 33(8.6) 21 (10.3) 12(6.7) 0.21
Neoplasia,n (%) 12(3.1) 4 (2.0) 8 (4.5) 0.16
Currentsmoking,n (%) 36(9.4) 20 (9.9) 16(8.9) 0.21
Alcoholabuse,n (%) 4 (1.1) 1 (0.5) 3 (1.7) 0.26
Electrocardiographyfindingsat randomization
Heart rate,mean ± SD(bpm) 62.2 ± 9.7 61.9 ± 9.8 62.6 ± 9.6 0.50
QRS > 120 ms,n (%) 43(11.3) 23 (11.4) 20(11.2) 0.95
LVH,n (%) 34(8.9) 19 (9.4) 15(8.4) 0.74
PathologicalQwaves,n (%) 11(2.9) 6 (3.0) 5 (2.8) 0.92
Concomitantcardiovascular therapies
Amiodarone,n (%) 148 (38.7) 74 (36.5) 74(41.3) 0.33
Sotalol,n (%) 28(7.3) 18 (8.9) 10(5.6) 0.22
Class Iantiarrhythmics,n (%) 127 (33.3) 68 (33.5) 59(33.0) 0.91
ACEinhibitors,n (%) 206 (53.9) 115 (56.7) 91(50.8) 0.26
CCBs,n (%) 108 (28.3) 54 (26.6) 54(30.2) 0.44
b-Blockers,n (%) 114 (29.8) 58 (28.6) 56(31.3) 0.56
Digitalis,n (%) 16(4.2) 10 (4.9) 6 (3.4) 0.44
Diuretics,n (%) 149 (39.0) 85 (41.9) 64(35.8) 0.22
Aldosteroneblockers,n (%) 20(5.2) 8 (3.9) 12(6.7) 0.23
Statins,n (%) 98(25.7) 53 (26.1) 45(25.1) 0.83
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all-cause hospitalizations occurredat a rate of 18.3%
(70 ⁄382) in the substudy and 20.3% (292 ⁄1442) in
themainstudy.
Biomarker concentrations in sinus rhythm and in AF
Baseline levels of the biomarkers are shown in
Table2.Concentrationsofallbiomarkerswerehigher
at the 6- and 12-month follow-up visits in patients
whowere inAF, compared to thosewhowere in sinus
rhythm(Table2).
NT-proBNP and MR-proANP significantly decreased
over the 1-year follow-up, although the decrease was
more marked over the first 6 months (Table 3).
Whereas copeptin did not change significantly, MR-
proADM and CT-proET1 slightly but significantly in-
creased.Thedecrease inNT-proBNPandMR-proANP
was significantly attenuated in patients with at least
one recurrence of AF over 1 year (Table 3: interaction
time · AF recurrence, P = 0.0005 and 0.0007,
respectively).
Baseline NT-proBNP, MR-proANP and hsTnT were
higher in patients older than 70 years, in those with
heart failure and ⁄or left ventricular ejection fraction
<40%, and those with coronary artery disease (data
not shown). Reduced renal filtration (estimated glo-
merular filtration rate £60 ml min)1 1.73 m)2) was
associated with significantly higher concentrations
of all six biomarkers (all P < 0.01). The six biomar-
kers significantly correlated with each other
(P < 0.001), with Spearman nonparametric correla-
tion coefficients ranging from 0.20 to 0.78 (the high-
est value was between NT-proBNP and MR-pro-
ANP).
When the concentrations of biomarkers were analy-
sedbytime, indays fromthe lastqualifyingcardiover-
sion before randomization, lower concentrations of
biomarkers were associated with longer time inter-
vals from cardioversion. The most remarkable rela-
tion was observed for NT-proBNP: 1–7 days, 246
pg mL)1; 7–16 days, 209 pg mL)1; >16 days, 151
pg mL)1 (Kruskal–Wallis test, P < 0.0001). Similar
relations were found for hsTnT (P = 0.04) and MR-
proANP(P = 0.02),butnot for theothermarkers.
Biohumoral predictors of recurrence of AF
Kaplan–Meier curves for probability of first recur-
renceofAFbymedianlevelsofbaselinehsTnTstarted
to diverge after the first 30 days of follow-up (Fig. 1;
log-rank test, P = 0.04). Similar trends were also
found for NT-proBNP (P = 0.08) and MR-proANP
(P = 0.07), whereas no differences were observed for
theother threevasoactivepeptides.
For those patients who experienced a recurrence of
AF (n = 203), an inverse relation was found between
the baseline concentration of the twonatriuretic pep-
tides (NT-proBNP and MR-proANP), but not of other
markers, and the time to develop the first AF recur-
rence (Fig.2).
Baseline concentrations of the three specific cardiac
biomarkers (hsTnT, NT-proBNP and MR-proANP)
independently predicted recurrence of first AF, after
adjustment for patient characteristics (Coxmultivar-
iate model, Table 4). Adjusted hazard ratios (HRs)
[95%CI for1 SDincrement]were1.15 [1.04–1.28] for
hsTnT (P = 0.007), 1.24 [1.11–1.39] for NT-proBNP
(P = 0.0001) and 1.15 [1.01–1.30] for MR-proANP
(P = 0.04). CT-proET-1 was also associated with the
risk of first recurrence of AF (1.16 [1.01–1.33],
P = 0.03). The risk of having more than one episode
over the 1-year follow-up periodwas not predicted by
anyof thesixbiomarkers (datanotshown).ROCanal-
ysis for hsTnT, NT-proBNP and MR-proANP yielded
specificities ranging from 0.49 to 0.57 and sensitivi-
ties ranging from 0.50 to 0.65, with optimal cut-off
values of 7.3 pg mL)1, 206 pg mL)1 and 165 pmol
Table 1 (Continued )
Characteristics
Allpatients
(n = 382)
Patientswith‡1
recurrenceofAF
(n = 203)
Patientswithout
recurrenceofAF
(n = 179) Pvalue
Oralanticoagulants,n (%) 233 (61.0) 126 (62.1) 107 (59.8) 0.65
Aspirin,n (%) 101 (26.4) 55 (27.1) 46 (25.7) 0.76
Randomized treatment,valsartan,n (%) 186 (48.7) 106 (52.2) 80 (44.7) 0.14
AF, atrial fibrillation; ACE, angiotensin-converting enzyme; BMI, body mass index; CCB, calcium channel blocker; COPD,
chronicobstructivepulmonarydisease; eGFR,estimatedglomerularfiltrationrate;LVH, leftventricularhypertrophy.
a109patientshadbothentrycriteria.
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L)1, respectively. Except for hsTnT (P = 0.01),noneof
the biomarkers had a C-statistic significantly differ-
ent from the line of no discrimination. The C-statistic
increased for the prediction of first AF recurrence
when all six biomarkers were incorporated into a
model with clinical risk factors and NT-proBNP (AU-
ROCfrom0.590to0.602,P = 0.02).
Patients were then divided according to relative
changes of biomarker concentrations (aboveorbelow
median) over the first 6 months of follow-up. Recur-
rence of AF within the subsequent 6 months was
more frequent in patients with above the median
changes in MR-proANP (141 patients with relative
changes from )9% to +1380%; 60.9% of these pa-
tients had an episode of AF recurrence) than in those
with below the median changes (141 patients with
relativechanges from)82%to)9%;39.1%ofpatients
withAF recurrence,P = 0.01),withaunivariateHRof
1.77 [1.15–2.72] (P = 0.009).Afteradjustment for rel-
evant clinical risk factors, the risk of recurrence of AF
in patients with above the median 6-month changes
in MR-proANP was still moderately elevated but no
longer significant (HR 1.53 [0.98–2.37], P = 0.06).
Similarly, recurrence of AF tended to be more
frequent in patients with above the median changes
in NT-proBNP (142 patients with relative changes
from )21% to +786%; 58.1% of patients with AF
(a)
(c)
(e)
(b)
(d)
(f)
Fig. 1 Kaplan–Meier curves for probability of first recurrence of atrial fibrillation by median of baseline concentrations of (a)
hsTnT, (b)NT-proBNP, (c)MR-proANP, (d)MR-proADM, (e)CT-proET,and (f) copeptin.
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recurrence) than in those with below the median
changes (142 patients with relative changes from
)99%to)21%;41.9%ofpatientswithAF recurrence,
P = 0.07). Univariate HR was 1.57 [1.02–2.41]
(P = 0.04) but was no longer significant after adjust-
ment (P = 0.29). Relative changes over time for the
other four biomarkers were not associated with sub-
sequentAFrecurrence.
Biohumoral predictors of all-cause and cardiovascular hospitalizations
One-year incidences ofhospitalizations for anycause
and for cardiovascular reasons were 20.2% and
15.4%, respectively, in the main study, and 18.7%
and 16.3%, respectively, in the 382 patients in the
substudy. The three cardiac biomarkers were inde-
pendently associated with the outcomes of hospital-
ization for any reason or for cardiovascular reasons,
afteradjustment forpatientcharacteristics (Coxmul-
tivariate models, Table 4). MR-proADM and CT-
proET-1predictedhospitalization foranyreason.
Discussion
Predicting recurrence of AF in patients in sinus
rhythmwithahistory ofAF isadifficult task [23]. Few
prospective studies to address this issue have identi-
fied a limited set of clinical variables [24]. Amongst
the biomarkers tested in small groups of patients, C-
reactive protein, brain natriuretic peptide and NT-
proBNPwere found to predict recurrence of AF in pa-
tientswith comorbidities [3–7].Weshowed in382pa-
tients,with53%1-year incidence of afirst recurrence
of AF, that: (i) several cardiovascularmarkers are ele-
vated during episodes of AF,when compared to sinus
rhythm; (ii) markers of cardiac injury and ⁄or strain
(hsTnT,MR-proANP andNT-proBNP) and endothelin
(CT-proET-1) have a modest but statistically signifi-
cant predictive power of recurrence of AF; (iii) the
higher the concentration of NT-proBNP, the earlier
the onset of AF; and (iv) changes over time in the con-
centration of one of these biomarkers (MR-proANP)
were also associated with subsequent recurrence of
AF.
Toourknowledge, dataon theprognostic value of cir-
culatingcardiac troponinassayedusingahighlysen-
sitive method and of a stable fragment of a precursor
of atrial natriuretic peptide have not been previously
reported inpatientswithahistoryofAF.
Thefinding thatmodestly elevated concentrations (in
almost 50% of cases within the accepted normal
range) of three specific cardiac markers and endo-
thelin predict recurrence of AF suggests that even a
subclinical chronic condition of cardiac strain ⁄ injury
may influenceAF recurrence.Theuseof angiotensin-
converting enzyme inhibitors (53.9%) and b-blockers
(29.8%) in these patients with hypertension (84.8%)
and heart failure (11%)may have contributed to low-
ering the concentrations of natriuretic peptides [25,
26].
The finding that the more recent the last cardiover-
sion, the higher the concentration of cardiacmarkers
at randomization supports the association of the lat-
terwith cardiac stress inducedbyor facilitatingAF.A
pathophysiological difference between predictors of
recurrent AF andmarkers of ongoing AF is suggested
by more elevated concentrations of several markers
during episodes of AF as shown by scheduled ECG
recordings togetherwithbloodsamplingat the6-and
12-month visits.Endothelin-1was found tobesignif-
icantly more elevated in patients with chronic heart
failurewhohadanewepisodeofAF inthesubsequent
23 months in the Val-HeFT trial [11] and was found
toplaya role inAFpathogenesis [14,15].
In general, either previous or concomitant AF at any
time over 1 year of follow-up (Table 2) was associated
withhigherconcentrationsofcardiovascularbiomar-
kers.Thissuggests that indeedneurohumoralactiva-
tion induced ⁄sustained by AF was still present after
recent conversion to sinus rhythm. By contrast, the
remarkable stability of the concentrationsofmarkers
Fig. 2 Time to first recurrence of atrial fibrillation by tertiles
ofbaselineconcentrationsof thenatriureticpeptides,N-termi-
nal proBNP andmid-regional proANP. P value determined by
Kruskal–Wallis test.T, tertile.
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in patients in sinus rhythm supports the lack of bio-
humoralactivation inthesepatients.
Several studies have shown elevations of cardiac bio-
markers in patients with AF and subsequent de-
creases once sinus rhythm has been restored [2, 4,
27, 28], but the underlying pathophysiology may be
different in the case of recurrence of AF in patients in
sinus rhythm with a history of AF, as in the present
study. Although only markers of cardiac strain ⁄ in-
jurywere found to have predictive value,MR-proANP
that is considered to be a more specific marker of at-
rial remodelling [29] showed a predictive power as
modest as that of a ‘ventricular’ marker such as NT-
proBNP.
Study limitations
This study enrolled mostly (84.8%) hypertensive pa-
tients with other diseases being under-represented;
thus, the possible effects of comorbidities on the pre-
dictive power of these biomarkers cannot be as-
sessed. Although the number of patients was larger
than in any other published study in a similar set-
ting, wemay still havemissed a relationship between
biomarkers and outcomes. We estimated that we
had at least 80% power (at a = 0.05) to detect an ef-
fect size of 1.34, 1.39 and 1.38 (expressed as HR) for
>median versus £median NT-proBNP, hsTnT and
MR-proANP, respectively, and first recurrence of AF.
Indeed, the relatively weak association of these bio-
markers to risk of first recurrence of AF, as evidenced
by Cox multivariate analysis and by low AUROC val-
ues, is not surprising because of the scarcity of pre-
dictive markers (either clinical or instrumental) in
this field, and the concentrations of these biomar-
kers in our patients being in the normal range or only
slightly elevated. The fact that risk of hospitalization
for any cause or for cardiovascular reasons was
predicted by the three cardiac markers supports
the internal consistency of the sample studied. In
other words, the sample size appears to be adequate
to detect a predictive role of the cardiac biomarkers
for clinical events, even at almost normal baseline
levels.
Conclusions
Cardiovascular biomarkers are weakly associated
with recurrent AF in patients in sinus rhythm who
had either two ormore documented episodes of AF in
the previous 6 months or successful cardioversion
for AF in the previous 2 weeks. Considering that the
number of patients studied was higher than in most
previously published studies to date, the weak pre-
dictive power observed is probably a better estimate
than the previously reported more striking associa-
tions in smaller populations. The temporal relation
betweenAFoccurrenceor recurrenceand levels of bi-
omarkers supports the pathophysiological consis-
tency of the observed associations. Consistent with
this is the paucity of predictors of AF recurrence,
including ECG variables, in a post hoc analysis of all
1442 patients included in the GISSI-AF trial [30].
Even considering the number of patients and the
duration of follow-up, the high incidence of outcome
events (53.1%) in this study enabled identification of
three cardiac markers for testing in future ad hoc
studies in this relativelyunexploredfield.
Conflict of interest statement
Drs Latini and Masson have received honoraria and
grantsupport fromB.R.A.H.M.S.AGandRocheDiag-
nostics.DrZdunek is an employee ofRocheDiagnos-
tics. Dr Struck is an employee of B.R.A.H.M.S. AG,
whichholds patent rights to themarkers.Drs. Latini,
Masson, Barlera, Maggioni, Staszewsky, Franzosi
andDisertori received institutional research support
from Novartis Pharma. Reagents for measuring
circulating biomarkers were kindly provided by
B.R.A.H.M.S. AG and Roche Diagnostics. No other
potential conflicts of interest relevant to this article
were reported.
Acknowledgements
TheGISSI studies aswell as thepresent substudyare
supportedby theAssociazioneNazionaleMedici Car-
diologi Ospedalieri and the Istituto di Ricerche Far-
macologiche Mario Negri. Funding was provided by
Novartis, which had no role in the design or conduct
of the trial, the collection, analysis, or interpretation
of thedata,or thewritingof thereport.
References
1 FusterV,Ryde´nLE,AsingerRWetal.ACC ⁄AHA ⁄ESCGuidelines
for theManagementofPatientsWithAtrialFibrillation:Executive
Summary A Report of the American College of Cardiology ⁄
American Heart Association Task Force on Practice Guidelines
and the European Society of Cardiology Committee for Practice
Guidelines and Policy Conferences (Committee to Develop
Guidelines for the Management of Patients With Atrial Fibril-
lation) Developed in Collaboration With the North American
Society of Pacing and Electrophysiology. Circulation 2001; 104:
2118–50.
2 Rossi A, Enriquez-SaranoM,Burnett Jr JC, LermanA, AbelMD,
Seward JB. Natriuretic peptide levels in atrial fibrillation: a pro-
R. Latini et al. | Biomarkers of AF recurrence
ª 2010 The Association for the Publication of the Journal of Internal Medicine Journal of Internal Medicine 269; 160–171 169
spective hormonal and Doppler-echocardiographic study. J Am
CollCardiol2000;35:1256–62.
3 Lellouche N, Berthier R, Mekontso-Dessap A et al.Usefulness of
plasmaB-type natriuretic peptide in predicting recurrence of at-
rialfibrillationoneyearafter external cardioversion.AmJCardiol
2005;95:1380–2.
4 Yamada T, Murakami Y, Okada T et al. Plasma atrial natriuretic
peptide and brain natriuretic peptide levels after radiofrequency
catheter ablation of atrial fibrillation. Am J Cardiol 2006; 97:
1741–4.
5 Liu T, Li G, Li L, Korantzopoulos P. Association between C-reac-
tive protein recurrence of atrial fibrillation after successful elec-
trical cardioversion: ameta-analysis. JAmCollCardiol2007;49:
1642–8.
6 LoricchioML,CianfroccaC, Pasceri V et al.Relation ofC-reactive
protein to long-term risk of recurrence of atrial fibrillation after
electricalcardioversion.AmJCardiol2007;99:1421–4.
7 Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Arnesen H,
Smith P. Candesartan, NT-proBNP and recurrence of atrial
fibrillation after electrical cardioversion. Int J Cardiol 2009; 131:
234–9.
8 Vasan RS, LarsonMG, Levy D et al.Doppler transmitral flow in-
dexes and risk of atrial fibrillation (the Framingham Heart
Study).AmJCardiol2003;91:1079–83.
9 KurlS,Ala-KopsalaM,RuskoahoHetal.PlasmaN-terminal frag-
ments of natriuretic peptides predict the risk of stroke and atrial
fibrillation inmen.Heart2009;95:1067–71.
10 Badran HM, Eid MA, Michael A. Doppler-derived indexes and
B-type natriuretic peptide in prediction of paroxysmal atrial
fibrillation in essential hypertension: a prospective study.
Echocardiography2007;24:911–22.
11 Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the
incidence of atrial fibrillation in patients with heart failure:
results from the Valsartan Heart Failure Trial (Val-HeFT). Am
HeartJ2005;149:548–57.
12 Wazni OM, Martin DO, Marrouche NF et al. Plasma B-type
natriuretic peptide levels predict postoperative atrial fibrillation
in patients undergoing cardiac surgery. Circulation 2004; 110:
124–7.
13 GISSI-AF Investigators, Disertori M, Latini R et al. Valsartan for
prevention of recurrent atrial fibrillation. N Engl J Med 2009;
360:1606–17.
14 DuruF,BartonM, Lu¨scher TF, CandinasR. Endothelin and car-
diac arrhythmias: do endothelin antagonists have a therapeutic
potential as antiarrhythmic drugs? Cardiovasc Res 2001; 49:
272–80.
15 Nakazawa Y, Ashihara T, Tsutamoto T, Ito M, Horie M. Endo-
thelin-1 as a predictor of atrial fibrillation recurrence after pul-
monaryvein isolation.HeartRhythm2009;6:725–30.
16 Gegenhuber A, Struck J, Dieplinger B et al.Comparative evalua-
tion of B-type natriuretic peptide, mid-regional pro-A-type natri-
uretic peptide, mid-regional pro-adrenomedullin, and Copeptin
to predict 1-year mortality in patients with acute destabilized
heart failure.JCardFail2007;13:42–9.
17 StoiserB,Mo¨rtlD,Hu¨lsmannM et al.Copeptin, a fragmentof the
vasopressin precursor, as a novel predictor of outcome in heart
failure.EurJClin Invest2006;36:771–8.
18 Disertori M, Latini R, Maggioni AP et al. Rationale and design of
the GISSI-Atrial Fibrillation Trial: a randomized, prospective,
multicentre study on the use of valsartan, an angiotensin II AT1-
receptor blocker, in the prevention of atrial fibrillation recur-
rence.JCardiovascMed (Hagerstown)2006;7:29–38.
19 Masson S, Latini R, Anand IS et al. Direct comparison of B-type
natriuretic peptide (BNP) and amino-terminal proBNP in a large
population of patients with chronic and symptomatic heart fail-
ure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem
2006;52:1528–38.
20 Latini R, Masson S, Anand IS et al. Prognostic value of very low
plasma concentrations of troponin T in patients with stable
chronicheart failure.Circulation2007;116:1242–9.
21 GiannitsisE,KurzK,HallermayerK,JarauschJ,Jaffe AS,Katus
HA. Analytical validation of a high-sensitivity cardiac troponin T
assay.ClinChem2010;56:254–61.
22 PencinaMJ,DAgostinoRB.OverallCasameasureofdiscrimina-
tion in survival analysis: model specific population value and
confidence intervalestimation.StatMed2004;23:2109–23.
23 Benjamin EJ, Chen PS, BildDE et al. Prevention of atrial fibrilla-
tion: report fromanationalheart, lung,andblood institutework-
shop.Circulation2009;119:606–18.
24 Raitt MH, Volgman AS, Zoble RG et al. Prediction of the recur-
rence of atrial fibrillation after cardioversion in theAtrial Fibrilla-
tion Follow-up Investigation of Rhythm Management (AFFIRM)
study.AmHeart J2006;151:390–6.
25 FungJW,YuCM,YipG etal.Effect of beta blockade (carvedilol or
metoprolol) on activation of the renin-angiotensin-aldosterone
system and natriuretic peptides in chronic heart failure. Am
JCardiol2003;92:406–10.
26 McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesar-
tan, enalapril, and their combination in congestive heart failure:
randomized evaluation of strategies for left ventricular dysfunc-
tion (RESOLVD)pilotstudy.TheRESOLVDPilotStudy Investiga-
tors.Circulation1999;100:1056–64.
27 Mo¨llmann H, Weber M, Elsa¨sser A et al. NT-ProBNP predicts
rhythmstability after cardioversion of lone atrial fibrillation.Circ
J2008;72:921–5.
28 Sacher F, Corcuff JB, Schraub P et al. Chronic atrial fibrillation
ablation impact on endocrine andmechanical cardiac functions.
EurHeartJ2008;29:1290–5.
29 YoshiharaF,NishikimiT,SasakoYetal.Plasmaatrialnatriuretic
peptideconcentration inverselycorrelateswith leftatrialcollagen
volume fraction inpatientswith atrial fibrillation: plasmaANPas
apossiblebiochemicalmarker topredict theoutcomeof themaze
procedure.JAmCollCardiol2002;39:288–94.
30 DisertoriM, Lombardi F, Barlera S et al.Clinical predictors of at-
rial fibrillation recurrence in the GISSI-AF trial. Am Heart J,
2010;159:857–63.
Appendix
Participating centres and investigators
Switzerland – Lugano (MG Rossi). Italy – Bagno a Ri-
poli (A Fazi), Bari Carbonara (O Pierfelice), Bergamo
(A Gavazzi, F Taddei), Bovolone (G Rigatelli, S Boni),
Bussolengo (R Trappolin), Casarano (A Muscella),
Caserta (A Vetrano), Catania (M Gulizia, GM Fran-
cese), Catanzaro (F Perticone), Citta` di Castello (D
Severini), Cremona (SPirelli, A Spotti, MMariani), Fi-
denza (P Pastori), Firenze (GM Santoro, C Minneci),
Napoli Federico II (P Perrone Filardi), Palermo Cerv-
ello (L Buffa), Palermo Villa Sofia (F Ingrillı`), Pavia (L
Tavazzi, C Belvito), Pesaro (A Pierantozzi), Pietra
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Ligure (A Nicolino), Reggio Calabria (G Pulitano`, A
Ruggeri, GCutrupi), Roma (MVolpe), Saluzzo (SRey-
naud), San Bonifiacio (R Rossi, E Carbonieri, E
Zampieri), SanDaniele del Friuli (LMos,GMarcuzzi),
SanMarcoArgentano (OCuccurullo), Sarzana (RPet-
acchi,DBertoli),Terni (MBernardinangeli,GProietti,
G Proietti), Trento Villa Bianca (G Cioffi, E Buck-
owska), Trento Santa Chiara (P Zeni, C Giovannelli),
Trieste ASL1 (CMazzone,DRadini), TriesteOspedali
Riuniti (AAleksova).
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